栄研化学の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2025/03/18 | 2,339 | 2,340 | 2,271 | 2,281 | -46 | -2% | 123,100 |
2025/03/17 | 2,314 | 2,350 | 2,314 | 2,327 | +14 | +0.6% | 103,000 |
2025/03/14 | 2,300 | 2,313 | 2,294 | 2,313 | +7 | +0.3% | 103,100 |
2025/03/13 | 2,300 | 2,323 | 2,295 | 2,306 | +6 | +0.3% | 81,600 |
2025/03/12 | 2,307 | 2,330 | 2,298 | 2,300 | -18 | -0.8% | 99,900 |
2025/03/11 | 2,289 | 2,333 | 2,265 | 2,318 | +40 | +1.8% | 167,300 |
2025/03/10 | 2,280 | 2,290 | 2,265 | 2,278 | -6 | -0.3% | 80,300 |
2025/03/07 | 2,231 | 2,298 | 2,231 | 2,284 | +3 | +0.1% | 108,000 |
2025/03/06 | 2,268 | 2,303 | 2,264 | 2,281 | +14 | +0.6% | 97,000 |
2025/03/05 | 2,278 | 2,288 | 2,259 | 2,267 | +35 | +1.6% | 94,100 |
2025/03/04 | 2,210 | 2,248 | 2,202 | 2,232 | +35 | +1.6% | 94,400 |
2025/03/03 | 2,200 | 2,213 | 2,186 | 2,197 | +12 | +0.5% | 77,700 |
2025/02/28 | 2,181 | 2,220 | 2,177 | 2,185 | +12 | +0.6% | 124,800 |
2025/02/27 | 2,167 | 2,182 | 2,153 | 2,173 | -5 | -0.2% | 76,800 |
2025/02/26 | 2,215 | 2,215 | 2,164 | 2,178 | -41 | -1.8% | 92,800 |
2025/02/25 | 2,149 | 2,256 | 2,148 | 2,219 | +73 | +3.4% | 181,500 |
2025/02/21 | 2,141 | 2,158 | 2,132 | 2,146 | +3 | +0.1% | 99,200 |
2025/02/20 | 2,132 | 2,153 | 2,121 | 2,143 | -36 | -1.7% | 115,800 |
2025/02/19 | 2,221 | 2,221 | 2,168 | 2,179 | -64 | -2.9% | 106,200 |
2025/02/18 | 2,300 | 2,318 | 2,236 | 2,243 | -17 | -0.8% | 130,300 |
2025/02/17 | 2,252 | 2,283 | 2,248 | 2,260 | +10 | +0.4% | 93,400 |
2025/02/14 | 2,221 | 2,252 | 2,221 | 2,250 | +69 | +3.2% | 174,300 |
2025/02/13 | 2,162 | 2,189 | 2,158 | 2,181 | +56 | +2.6% | 78,000 |
2025/02/12 | 2,145 | 2,145 | 2,107 | 2,125 | -20 | -0.9% | 83,800 |
2025/02/10 | 2,140 | 2,161 | 2,135 | 2,145 | +5 | +0.2% | 76,500 |
2025/02/07 | 2,142 | 2,183 | 2,135 | 2,140 | -2 | -0.1% | 85,600 |
2025/02/06 | 2,170 | 2,178 | 2,141 | 2,142 | -1 | ±0% | 84,700 |
2025/02/05 | 2,123 | 2,171 | 2,123 | 2,143 | +53 | +2.5% | 137,900 |
2025/02/04 | 2,150 | 2,174 | 2,075 | 2,090 | -73 | -3.4% | 239,500 |
2025/02/03 | 2,150 | 2,184 | 2,137 | 2,163 | +25 | +1.2% | 148,800 |
2025/01/31 | 2,151 | 2,160 | 2,123 | 2,138 | -13 | -0.6% | 126,200 |
2025/01/30 | 2,148 | 2,159 | 2,140 | 2,151 | +12 | +0.6% | 96,700 |
2025/01/29 | 2,177 | 2,177 | 2,139 | 2,139 | -22 | -1% | 100,400 |
2025/01/28 | 2,164 | 2,175 | 2,154 | 2,161 | -31 | -1.4% | 111,200 |
2025/01/27 | 2,188 | 2,197 | 2,170 | 2,192 | +6 | +0.3% | 72,400 |
2025/01/24 | 2,169 | 2,199 | 2,169 | 2,186 | +23 | +1.1% | 66,700 |
2025/01/23 | 2,151 | 2,172 | 2,151 | 2,163 | +3 | +0.1% | 56,100 |
2025/01/22 | 2,179 | 2,179 | 2,149 | 2,160 | +10 | +0.5% | 49,300 |
2025/01/21 | 2,153 | 2,161 | 2,145 | 2,150 | -1 | ±0% | 96,700 |
2025/01/20 | 2,163 | 2,180 | 2,151 | 2,151 | +3 | +0.1% | 81,500 |
2025/01/17 | 2,143 | 2,164 | 2,143 | 2,148 | +1 | ±0% | 88,400 |
2025/01/16 | 2,151 | 2,163 | 2,144 | 2,147 | -4 | -0.2% | 104,200 |
2025/01/15 | 2,159 | 2,187 | 2,146 | 2,151 | -5 | -0.2% | 126,800 |
2025/01/14 | 2,143 | 2,170 | 2,142 | 2,156 | +3 | +0.1% | 105,600 |
2025/01/10 | 2,150 | 2,166 | 2,145 | 2,153 | -9 | -0.4% | 79,200 |
2025/01/09 | 2,151 | 2,170 | 2,147 | 2,162 | -1 | ±0% | 97,700 |
2025/01/08 | 2,179 | 2,185 | 2,154 | 2,163 | -16 | -0.7% | 82,200 |
2025/01/07 | 2,150 | 2,182 | 2,142 | 2,179 | +34 | +1.6% | 78,200 |
2025/01/06 | 2,178 | 2,199 | 2,143 | 2,145 | ±0 | ±0% | 150,100 |
2024/12/30 | 2,190 | 2,221 | 2,142 | 2,145 | -20 | -0.9% | 98,300 |
101~
150
件表示中 / 7015件
類似銘柄と比較する
現在ご覧いただいている「栄研化」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
栄研化 | 234,600円 | +4.1% | -3.1% | 2.47% | 20.38倍 | 1.78倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
ゼリア新薬 | 203,300円 | +3.1% | -6.5% | 2.36% | 9.43倍 | 1.00倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
杏林製薬 | 156,100円 | -2.4% | -52.3% | 3.65% | 18.68倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ネクセラファーマ | 93,500円 | +20.3% | - | 0.00% | 165.78倍 | 1.29倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 63,300円 | +14.3% | - | 3.16% | 25.73倍 | 1.64倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
市場注目の銘柄
チャート関連のコラム